| 摘要: |
| 目的:研究醛固酮受体拮抗剂螺内酯对扩张型心肌病神经内分泌的影响,探讨其治疗扩张型心肌病的可能机制。方法:体质量为(300±50) g的雄性SD大鼠,腹腔注射多柔比星2 mg/kg（每周1次、共8周）建立扩张型心肌病心衰模型,随机分为4组(n=10):模型组、螺内酯干预Ⅰ组、螺内酯干预Ⅱ组、螺内酯干预Ⅲ组,模型组采用生理盐水10 ml/(kg·d)灌胃,螺内酯Ⅰ组、Ⅱ组、Ⅲ组分别灌胃10、20、40 mg/(kg·d)螺内酯,连续给药8周，于给药后第9周检测血浆、心肌中血管紧张素Ⅱ(AngⅡ)、醛固酮(ALD)水平,并检测血浆一氧化氮(NO)、血清Ⅲ型前胶原氨端肽(PⅢNP)及血浆心钠素(ANP)水平。结果:给予螺内酯干预8周后Ⅱ组、Ⅲ组血浆、心肌中AngⅡ水平下降（P<0.05）、ALD水平上升（P<0.05）、血浆NO水平上升（P<0.05）、PⅢNP水平下降（P<0.05）、ANP水平下降（P<0.05）。结论:予扩张型心肌病心力衰竭大鼠以螺内酯20 mg/(kg·d)及40 mg/(kg·d)治疗8周可一定程度纠正神经内分泌紊乱。 |
| 关键词: 螺内酯 扩张型心肌病 神经内分泌 |
| DOI：10.3724/SP.J.1008.2009.01022 |
| 投稿时间：2009-06-14修订日期：2009-07-30 |
| 基金项目: |
|
| Influence of spironolactone on neuroendocrine of SD rats with dilated cardiomyopathy |
| BAI Jie1,2,ZHANG Guo-hui1*,CHEN Rong1,SHENG Jia1,WANG Jian-fei1 |
| (1.Department of Cardiology,The First People’s Hospital,Jiangsu University,Zhenjiang 212002,China;2.Department of Geriatrics,Changhai Hospital,Second Military Medical University,Shanghai 200433) |
| Abstract: |
| Objective:To study the effect of spironolactone,an aldosterone receptor antagonist(ARA),on neuroendocrine of SD rats with dilated cardiomyopathy,so as to investigate its mechanism in treatment of dilated cardiomyopathy.Methods: Male SD rats,weighting (300±50) g,were intraperitoneally injected with adriamycin (2 mg/kg) once a week for 8 weeks to induce dilated cardiomyopathy models.The rat models were randomly divided into 4 groups: control group,low dose spironolactone group (10 mg/\[kg·d\],i.g.\],middle dose spironolactone group (20 mg/\[kg·d\],i.g.) and high dose spironolactone group (40 mg/\[kg·d\],i.g.).Rats in the normal control group received normal saline (10 mg/\[kg·d\],i.g.).Spironolactone was given for 8 weeks.Angiotensin Ⅱ(AngⅡ) and aldosterone (ALD) levels in the plasma and cardiac muscle homogenate were determined 9 weeks later.The plasma nitrogen monoside (NO),N-terminal popeptide of collagen type Ⅲ (PⅢNP) in serum and atrial natriuretic peptide (ANP) in the plasma were also measured.Results: Eight weeks after treatment,the Ang Ⅱ levels in the plasma of animals in the middle dose group and high dose group were significantly decreased(P<0.05),the levels of ALD were elevated(P<0.05),those of PⅢNP and ANP were decreased(all P<0.05).Conclusion: Spironolactone at 20 mg/(kg·d) or 40 mg/(kg·d) for 8 weeks can correct the disorder in neuroendocrine system to some extents. |
| Key words: spironolactone cardiomyopathy neuroendocrine |
